tetano
Editor, Senior Moderator
Clin Case Rep
. 2021 Jul 6;9(7):e04459.
doi: 10.1002/ccr3.4459. eCollection 2021 Jul.
Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir
Naohiro Oda[SUP] 1 [/SUP], Keiji Miyoshi[SUP] 2 [/SUP], Daisuke Morichika[SUP] 2 [/SUP], Yuka Beika[SUP] 2 [/SUP], Takahiro Taki[SUP] 1 [/SUP], Reo Mitani[SUP] 1 [/SUP], Toshiaki Okada[SUP] 2 [/SUP], Ichiro Takata[SUP] 1 [/SUP]
Affiliations
Abstract
COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.
Keywords: COVID‐19; baricitinib; immune checkpoint inhibitor; immune‐related adverse event; lung cancer.
. 2021 Jul 6;9(7):e04459.
doi: 10.1002/ccr3.4459. eCollection 2021 Jul.
Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir
Naohiro Oda[SUP] 1 [/SUP], Keiji Miyoshi[SUP] 2 [/SUP], Daisuke Morichika[SUP] 2 [/SUP], Yuka Beika[SUP] 2 [/SUP], Takahiro Taki[SUP] 1 [/SUP], Reo Mitani[SUP] 1 [/SUP], Toshiaki Okada[SUP] 2 [/SUP], Ichiro Takata[SUP] 1 [/SUP]
Affiliations
- PMID: 34257986
- PMCID: PMC8259795
- DOI: 10.1002/ccr3.4459
Abstract
COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.
Keywords: COVID‐19; baricitinib; immune checkpoint inhibitor; immune‐related adverse event; lung cancer.